Merck & Co gets subpoena over cancer and antiviral drug marketing in USA

9 August 2011

Merck & Co (NYSE: MRK) has received a subpoena from the US Department of Justice as part of a criminal investigation requesting details of the marketing and selling of three prescription medicines, acquired along with its acquisition of Schering-Plough in 2009, from January 1, 2004 to the present, the US drugs giant revealed in its quarterly filing with the Securities and Exchange Commission.

The products in question are the brain cancer treatment Temodar (temozolomide), hepatitis C drug PegIntron (pegylated interferon alfa-2b), and cancer therapy Intron A (interferon alfa-2b). Sales of the drugs for the first half of this year totaled $481 million, $319 million and $96 million, respectively (The Pharma Letter August 1).

The revelation saw Merck’s shares fall 5.6% to $29.94 yesterday, albeit in a sharply declining market, when the S&P plunged 6.7% and largely triggered by that agency’s downgrade of America’s debt rating. This was the lowest level for the company since August 2009, noted a Bloomberg report. Merck said it is cooperating with the DoJ investigation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical